Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin

Journal of Viral Hepatitis

Volumn 15, Issue 5, 2008, Pages 363-369

  Nunez M ^a,b   Ocampo, A ^c   Aguirrebengoa, K ^d   Cervantes, M ^e   Pascual, A ^f   Echeverria, S ^g   Asensi, V ^h   Barreiro, P ^a   Garcia Samaniego, J ^a   Soriano, V ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c HOSPITAL XERAL CÍES   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e HOSPITAL DE SABADELL   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Anaemia; Hepatitis C; HIV; Pegylated interferon; Ribavirin

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; ZIDOVUDINE;

ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; VIROLOGY;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; INTERFERON ALFA-2A; MALE; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; WITHHOLDING TREATMENT; ZIDOVUDINE;

EID: 41549163313     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00952.x     Document Type: Article

References (17)

1. Dienstag J, McHutchison J. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 264.
2. Tappero G, Ballare M, Farina M, Negro F. Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. J Hepatol 1998 29 : 1033 1034.
3. McHutchison J, Manns M, Longo D. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006 26 : 389 398.
4. Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. J Viral Hepat 2004 11 : 84 87.
5. Rendon A, Nunez M, Romero M et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005 39 : 401 405.
6. Richmann D, Fischl M, Grieco M et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1998 317 : 192 197.
7. Lutton J, Mathew A, Levere R, Abraham N. Role of heme metabolism in AZT-induced bone marrow toxicity. Am J Hematol 1990 35 : 1 5.
8. Núñez M, Miralles C, Berdún M et al. Role of weight-based ribavirin dosing and extended duration of therapy in the treatment of chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Human Retroviruses 2007 23 : 972 982.
9. Takaki S, Tsubota A, Hosaka T et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004 39 : 668 673.
10. Sulkowski M, Wasserman R, Brooks L, Ball L, Gish R. Changes in hemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004 11 : 243 250.
11. Hung C, Lee C, Lu S et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006 26 : 1079 1086.
12. Henry D, Slim J, Lamarca A, Bowers P, Leitz G, for the HIV/HCV Coinfection Natural History Study Group. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. AIDS Res Human Retroviruses 2007 23 : 1 9.
13. Alvarez D, Dieterich D, Brau N, Moorehead L, Ball L, Sulkowski M. Zidovudine use but not weight-based ribavirin dosing impacts anemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006 13 : 683 689.
14. Reddy K, Shiffman M, Morgan T et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 5 : 124 129.
15. Afdhal N, Dieterich D, Pockros P et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004 126 : 1302 1311.
16. Yachimski P, Chung R. Erythropoietin for treatment-related anemia in persons with hepatitis C - questions remain. AIDS Read 2004 14 : 568 569.
17. Shiffman M, Price A, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin and epoetin alfa. Hepatology 2007 46 : 371 379.